ML228 NEW
| Price | $37 | $89 | $153 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: ML228 | CAS No.: 1357171-62-0 |
| Purity: 99.54% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | ML228 |
| Description | ML228 is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF. |
| In vitro | ML228 introduces a new chemical class for researchers exploring HIF activation and its therapeutic applications. Unlike existing HIF activators, ML228's structure significantly diverges, notably absent of the acidic functional group typically found in PHD inhibitors—an attribute potentially crucial for specific disease contexts[1][2]. |
| In vivo | ML228 (injection; 1 µg/kg; 7 days) treatment following spinal cord injury (SCI) improves the local hypoxic-ischemic environment, reduces SCI secondary injury, and promotes neurological function recovery[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% (20% SBE-β-CD in Saline) : < 10 mg/mL (24.07 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 150 mg/mL (361.02 mM), Sonication is recommended. 10% DMSO+90% Saline : < 10 mg/mL (24.07 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : < 10 mg/mL (24.07 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% Corn oil : < 10 mg/mL (24.07 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. |
| Keywords | ML-228 | ML228 | ML 228 | HIF |
| Inhibitors Related | Deferoxamine Mesylate | Hydralazine hydrochloride | Dapagliflozin | Chlorogenic Acid | Glucosamine | Hydroxycitric acid tripotassium hydrate | Glucosamine hydrochloride | Chloramphenicol | Oroxylin A | Acriflavine Hydrochloride | Albendazole | Glucosamine sulfate |
| Related Compound Libraries | Glycometabolism Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Epigenetics Compound Library | Hematonosis Compound Library | Glutamine Metabolism Compound Library | Angiogenesis related Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY